Hydrochloric Acid → (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-Acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid hydrochloride

HRID 727595Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 727595
[C:1]([N:4]1[CH2:9][CH2:8][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:6][CH2:5]1)(=[NH:3])[CH3:2].[ClH:33]>O>[ClH:33].[C:1]([N:4]1[CH2:5][CH2:6][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:8][CH2:9]1)(=[NH:3])[CH3:2]

Komponenten

4

Versuchsvorschrift

200 mg of (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid [prepared as described in step (b) above] were dissolved in 5 ml of water, after which 0.43 ml of 1N aqueous hydrochloric acid was added. The resulting mixture was worked up and purified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque), using water as the eluent. Those fractions containing the title compound were combined and lyophilized to give 149 mg of the title compound as a powder.

Aufarbeitung

  1. custompurified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque),
  2. additionThose fractions containing the title compound

Quellen und Nachweise

ORD-Eintrag
ord-55c916a8c719440daef285ba638a7e8e
Quelldatensatz
uspto-grants-1998_01
Patentnummer
US05712267

Notizen zur Reaktion

Wird geladen…